



Supplementary Figure S3


A) Copy Number Samples with Purity $\geq 15\%$

B) Somatic Mutation Samples with Purity $\geq 5\%$




Supplementary Figure S4: Germline CNV around UGT2B17 and UGT2B15


A) UGT2B17 region Homozygous Gain




C) UGT2B17 region Heterozygous Del of UGT2B15



B) UGT2B17 region Homozygous Del




D) UGT2B17 region Diploid, 15 pct purity (no segmentation)




Supplementary Figure S5

Median SD of rescaled gene CNV relative to segmented CNV




Supplementary Figure S6

V2 Purity vs log10(TTTCV2 time) (p=0.08)





Supplementary Figure S8


Stress vs dfArray RNA Expression, High Quality






Supplementary Figure S9: RNA-seq QC





AR_01
 AR_06
 AR_03
 TGCCTTA_MIR124A
 GTGCCTT_MIR506
 AR_Q2
 ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP
 SOX5_UPREGULATED_MA_JNCI
 KONDO_PROSTATE_CANCER_HCP_WITH_H3K27ME3
 AR_Q2
 YEGNASUBRAMANIAN_PROSTATE_CANCER
 STEROID_BIOSYNTHETIC_PROCESS
 TMPRSS2ERG_INTERSTITIAL_GENES
 LIU_SOX4_TARGETS_DN
 GO_REGULATION_OF_INTRACELLULAR_STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY
 GO_NEGATIVE_REGULATION_OF_INTRACELLULAR_STEROID_HORMONE_RECEPTOR_SIGNALING_PATHWAY_DN
 HWAY_DN_PROSTATE_CANCER_TMPRSS2_ERG_FUSION
 NELSON_RESPONSE_TO_ANDROGEN_DN
 KONDO_EZH2_TARGETS
 ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_DN
 LIU_PROSTATE_CANCER_DN
 UP_WNT_ACTIVATION_KIM_CSC
 UP_WNT_CRPC_MURILLO_GARZON
 WANG_RESPONSE_TO_FORSKOLIN_DN
 HALLMARK_P13K_AKT_MTOR_SIGNALING
 PID_P13K1_AKT_PATHWAY
 GO_STEROID_HORMONE_RECEPTOR_BINDING
 GO_ANDROGEN_RECEPTOR_BINDING
 PID_AR_PATHWAY
 GO_ANDROGEN_RECEPTOR_SIGNALING_PATHWAY
 PID_AR_TF_PATHWAY
 KEGG_PROSTATE_CANCER
 LIU_SOX4_TARGETS_UP
 REACTOME_YAP1_AND_WWTR1_TAZ_STIMULATED_GENE_EXPRESSION
 PID_AR_NONGENOMIC_PATHWAY
 PID_RHOA_PATHWAY
 SOX4_TARGETS_CHRIS_SCHARER
 GO_HORMONE_RECEPTOR_BINDING
 KONDO_COLON_CANCER_HCP_WITH_H3K27ME1
 UP_PROSTATE_CANCER_TMPRSS2_ERG_FUSION
 KONDO_PROSTATE_CANCER_WITH_H3K27ME3
 REACTOME_STEROID_HORMONES
 REACTOME_ANDROGEN_BIOSYNTHESIS
 GO_ANDROGEN_METABOLIC_PROCESS
 GO_ANDROGEN_BIOSYNTHETIC_PROCESS
 JJ_PROSTATE_SIGNATURE_UP
 JJ_PROSTATE_SIGNATURE_UP
 LIU_PROSTATE_CANCER_UP
 SHARMA_CHRISO_AR_TARGET_CRPC
 AKT_UP_PROSTATE_BREAST_MTORINHIB_SENSITIVE
 AKT_UP_PROSTATE_BREAST_MTORINHIB_INSENSITIVE
 NELSON_RESPONSE_TO_ANDROGEN_UP
 HALLMARK_ANDROGEN_RESPONSE
 WANG_RESPONSE_TO_FORSKOLIN_UP
 WANG_RESPONSE_TO_ANDROGEN_UP
 GO_REGULATION_OF_ANDROGEN_RECEPTOR_SIGNALING_PATHWAY
 GO_NEGATIVE_REGULATION_OF_ANDROGEN_RECEPTOR_SIGNALING_PATHWAY
 JJ_PROSTATE_SIGNATURE_DN
 EZH2_UP_PROSTATE
 PTEN_DELETION_UP
 AR_LOSS_INHIBITION_DOWN
 DOWN_WNT_CRPC_MURILLO_GARZON
 PTEN_DELETION_DOWN



Supplementary Figure S10: V2 Geneset CNV






Supplementary Figure S11: V1 Geneset CNV




Supplementary Figure S12:

Genesets where Difference between V2 and V1 CNV is associated with response (TTTC)



Supplementary Figure S13: RNA-seq VDR & RXRG

VDR, V2-FDR=4.29e-02



RXRG, V2-FDR=1.27e-03

